Cholesterol Assimilation by Lactobacillus Probiotic Bacteria: An In Vitro Investigation

Abstract EN

Excess cholesterol is associated with cardiovascular diseases (CVD), an important cause of mortality worldwide.

Current CVD therapeutic measures, lifestyle and dietary interventions, and pharmaceutical agents for regulating cholesterol levels are inadequate.

Probiotic bacteria have demonstrated potential to lower cholesterol levels by different mechanisms, including bile salt hydrolase activity, production of compounds that inhibit enzymes such as 3-hydroxy-3-methylglutaryl coenzyme A, and cholesterol assimilation.

This work investigates 11 Lactobacillus strains for cholesterol assimilation.

Probiotic strains for investigation were selected from the literature: Lactobacillus reuteri NCIMB 11951, L.

reuteri NCIMB 701359, L.

reuteri NCIMB 702655, L.

reuteri NCIMB 701089, L.

reuteri NCIMB 702656, Lactobacillus fermentum NCIMB 5221, L.

fermentum NCIMB 8829, L.

fermentum NCIMB 2797, Lactobacillus rhamnosus ATCC 53103 GG, Lactobacillus acidophilus ATCC 314, and Lactobacillus plantarum ATCC 14917.

Cholesterol assimilation was investigated in culture media and under simulated intestinal conditions.

The best cholesterol assimilator was L.

plantarum ATCC 14917 (15.18 ± 0.55 mg/1010 cfu) in MRS broth.

L.

reuteri NCIMB 701089 assimilated over 67% (2254.70 ± 63.33 mg/1010 cfu) of cholesterol, the most of all the strains, under intestinal conditions.

This work demonstrates that probiotic bacteria can assimilate cholesterol under intestinal conditions, with L.

reuteri NCIMB 701089 showing great potential as a CVD therapeutic.